LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo

Cancer statistics, 2014

Rebecca L. Siegel, Jiemin Ma, Zhaohui Zou et al. · CA A Cancer Journal for Clinicians · 2014 · 11.5K citations · Full text

Epidemiology Of Cancer, Cancer Registration, United States +17

Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature

Peter Y. Park, Teresa A. Goldin, John C. S. Chang et al. · Case Reports in Oncology · 2015 · 5.3K citations · Full text

NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1

Denis C. Guttridge, Chris Albanese, Julie Y. Reuther et al. · Molecular and Cellular Biology · 1999 · 1.3K citations · Full text

Cyclin D1, Immunology, Immune Regulation +18

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer

John J. Rinehart, Alex A. Adjei, Patricia LoRusso et al. · Journal of Clinical Oncology · 2004 · 635 citations

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

Federica Di Nicolantonio, Sabrina Arena, Josep Tabernero et al. · Journal of Clinical Investigation · 2010 · 343 citations · Full text

Cancer Biology, Cellular Physiology, Tumor Biology +16